The Bromodomain: A New Target in Emerging Epigenetic Medicine

详细信息    查看全文

• 作者：Steven G. Smith ; Ming-Ming Zhou
• 刊名：ACS Chemical Biology
• 出版年：2016
• 出版时间：March 18, 2016
• 年：2016
• 卷：11
• 期：3
• 页码：598-608
• 全文大小：539K
• ISSN：1554-8937

文摘

The bromodomain (BrD) is a conserved protein modular domain found in many chromatin- and transcription-associated proteins that has the ability to recognize acetylated lysine residues. This activity allows bromodomains to play a vital role in many acetylation-mediated protein–protein interactions in the cell, ranging from substrate recruitment for histone acetyltransferases (HATs) to aiding in multiple-protein complex assembly for gene transcriptional activation or suppression in chromatin. In recent years, considerable efforts have been made to develop chemical inhibitors of these bromodomains in an effort to probe their cellular functions. Potent and selective inhibitors have been extensively developed for one group of the bromodomain family termed BET proteins that consist of tandem bromodomains followed by an extra terminal domain. Drug developers are actively designing inhibitors of other bromodomains and working to move the most successful inhibitors into the clinic.